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Abstract 
Background. Patients with WHO grade II glioma may respond to chemotherapy which is 
currently not standardized regarding timing and treatment duration. Metabolic changes 
during chemotherapy may precede structural tumor volume reductions. We therefore 
compared time courses of amino acid PET and MRI responses to temozolomide (TMZ), and 
assessed whether responses correlate with seizure control and progression-free survival 
(PFS). 
Methods. PET and MRI were performed before and during TMZ chemotherapy. Tumor 
volumes were calculated using regions-of-interest analysis. Amino acid uptake was also 
quantified as metabolically active tumor volume and tumor:cerebellum uptake ratio. 
Results: 125 PET and 125 MRI scans from 33 patients were analyzed. Twenty-five patients 
showed metabolic responses which exhibited an exponential time course with a 25% 
reduction of the active volume on average after 2.3 months. MRI responses followed a linear 
course with a 25% reduction after 16.8 months. Reduction of metabolically active tumor 
volumes, but not reduction of PET uptake ratios or MRI tumor volumes, correlated with 
improved seizure control following chemotherapy (p = 0.012). Receiver-operating-
characteristic curve analysis showed that a decrease of the active tumor volume of ≥80.5% 
predicts a PFS of ≥60 months (p = 0.018), and of ≥64.5% a PFS of ≥48 months (p = 0.037). 
Conclusions. Amino acid PET is superior to MRI to evaluate TMZ responses in WHO grade 
II glioma patients. The response delay between both imaging modalities favours amino acid 
PET to individually tailor chemotherapy duration. Additional studies should investigate 
whether this personalized approach is appropriate with regard to outcome. 
 
Key words: low-grade glioma – chemotherapy – PET – MRI - epilepsy 
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Introduction 
Diffuse cerebral WHO grade II gliomas often present with epileptic seizures and show 
insidious tumor growth.1 The natural history and response to treatment of these tumors is 
predominantly determined by genetic alterations such as co-deletion on chromosomal arms 
1p and 19q, isocitrate dehydrogenase 1 (IDH1/2) mutation and methylation of the O6-
methylguanine-DNA methyltransferase (MGMT) promoter.2,3 
Alkylating agent chemotherapy is active in patients with WHO grade II glioma. Once given 
at tumor progression or recurrence it yields objective response rates up to 60% and response 
durations of several years.4 In addition, chemotherapy can reduce the frequency of seizures. 
However, the evaluation of chemotherapy response based on MRI with T2-weighted and 
FLAIR MRI sequences is difficult.5 Accordingly, a reduction in seizure frequency has been 
proposed as a surrogate marker for a clinical benefit from chemotherapy.6,7 Currently there is 
no standard for the optimal drug choice, timing and duration of chemotherapy. The European 
Organization for Research and Treatment of Cancer trial 22033-26033 prescribed 12 cycles 
of temozolomide (TMZ) chemotherapy, while other groups treated patients as long as MRI 
showed at least evidence of stable disease.4 Interestingly, tumors may continue to shrink on 
MRI even after termination of chemotherapy.8,9 Using PET with the amino acid O-(2-
[18F]fluoroethyl)-L-tyrosine (FET) we reported rapid metabolic deactivation in WHO grade II 
glioma patients in response to TMZ.10 Our current study aimed to investigate metabolic 
responses in a large multicenter patient cohort treated with TMZ. We also assessed whether 
metabolic responses on PET correlate with seizure control and progression-free survival 
(PFS). 
 
Materials and Methods 
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Clinical data. Patients were retrospectively identified according to the following criteria: (i) 
supratentorial cerebral WHO grade II glioma at progression after surgery; (ii) no contrast 
enhancement on T1-weighted MRI; (iii) no previous radio- or chemotherapy; (iv) measurable 
disease on T2-weighted MRI before chemotherapy with two perpendicular diameters ≥ 10 
mm; (v) a MRI and amino acid PET schedule including a baseline evaluation and at least two 
examinations during and at the end of chemotherapy. Patient data were extracted from the 
hospital medical records and included demographic as well as tumor and treatment 
characteristics, PFS and overall survival (OS). Seizure frequencies before chemotherapy 
were documented during post-surgical surveillance in three-monthly intervals. During 
chemotherapy seizure frequencies were recorded monthly. We defined seizure control groups 
during chemotherapy as: group I = 0-50% seizure frequency reduction, group II = >50% 
reduction or seizure-free. 
Chemotherapy. TMZ chemotherapy was administered according to local policies (Table 1). 
Adverse effects were scored according to the Common Terminology Criteria for Adverse 
Events (CTCAE, version 4.0). 
Imaging data acquisition. Baseline imaging was performed within one month before 
chemotherapy initiation, and follow-up imaging started between 2 and 6 months thereafter. 
MRI examinations included T2-weighted and gadolinium-enhanced T1-weighted sequences 
according to clinical routine protocols on 1.5 or 3.0 Tesla MRI scanners. PET data were 
acquired after intra-venous administration of 150-240 MBq FET (Switzerland, Austria, 
Germany) or approximately 650 MBq L-[methyl-11C]methionine (MET, Italy). Grosu et al 
reported that both tracers yield virtually identical amino acid uptake values in gliomas.11 
Their whole cohort of gliomas WHO II-IV showed mean tumor:brain uptake ratios of 2.5 for 
FET and of 2.6 for MET which represents a difference of 4%. For the subgroup of WHO II 
gliomas uptake ratios differed by 1%.11 We therefore consider both MET and FET suitable to 
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comparably characterize low-grade gliomas on amino acid PET.  Static emission scans were 
acquired at the following time periods after tracer administration: 40-60 min (Switzerland; 
Discovery LS, GE Medical Systems), 30-45 min (Austria; Advance, GE Healthcare), 20-40 
min (Germany; ECAT Exact HR+, Siemens), 30-45 min (Italy; Discovery LS, GE 
Healthcare). After correction for random and scattered coincidences and dead time, images 
were reconstructed with the specific scanner software. The reconstructed image resolution 
was approximately 5.5 mm. 
Image data analysis, determination of response and progression. Response assessment on 
PET and MRI was centrally performed by M.Wy. (Nuclear Medicine) and U.R. and N.G. 
(Neurooncologists) with long-standing experience in PET and MRI analysis. Each patient 
served as his own control, and values during chemotherapy were expressed as percent from 
baseline, i.e. before the start of chemotherapy. Quantification of PET and MRI data was 
performed on co-registered images using PMOD (PMOD Technologies Ltd, Zurich, 
Switzerland).12 MRI tumor volumes were measured on T2-weighted axial sequences by 
manually outlining regions-of-interest (ROIs) around tissue exhibiting T2-hyperintensity. 
Finally, all tumor-containing slices were summed. Values during chemotherapy were 
expressed as percent change from baseline MRI before initiation of chemotherapy. Response 
was also determined according to the Response Assessment in Neuro-Oncology (RANO) 
criteria which quantify the product of the perpendicular tumor diameters on the slice showing 
the largest tumor area (mm2).5 The RANO criteria categorize size reductions between 25% 
and 50% as ‚minor response’, ≥50% as ‘partial response’, and disappearance of the lesion on 
T2–weighted or FLAIR MR imaging as ‘complete response’. ‘Objective response’ is the sum 
of minor response, partial response and complete response. Size increases of ≥25% are 
scored as ‚progressive disease’. ‘Stable disease’ is defined when MRI changes do not qualify 
for progression, or for complete, partial, or minor response. We diagnosed progression also if 
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new contrast enhancement on T1-weighted sequences or clinical signs (e.g. recurrence or new 
onset of seizures) were accompanied by tumor size increase less than 25%. 
Amino acid uptake was also quantified using ROI analysis. The cerebellum served as 
reference region. ROIs covering the whole cerebellum were drawn for each slice. Counts of 
all cerebellar ROIs were then averaged to produce the mean cerebellar amino acid uptake. 
For tumors three measures were used: First, the ‘metabolically active volume’ (cm3) was 
calculated as the tumor volume containing pixels >110% of the mean cerebellar amino acid 
uptake. We derived this threshold from our earlier methodological study.13 It corresponds 
well to the visual impression of active WHO grade II gliomas on PET.14 Second, the tumor 
amino acid uptake (counts) was determined by placing a ROI over the tumor on the PET slice 
with the largest extent and which was normalized to the mean cerebellar uptake (mean 
T:CBL ratio, unit-less). Third, peak uptake ratios were calculated by averaging all counts 
from tumor voxels which exhibited ≥95% of the maximum tumor radioactivity. In patients 
without active tumor volume, ROIs were placed on the T2-weighted MR images, and were 
then transferred to the corresponding PET planes. In line with our previous study10 we 
defined a metabolic treatment response as a reduction of 10% or more from the initial tumor 
volume (active PET volume) on at least two subsequent time points at least 4 weeks apart 
after the initiation of chemotherapy. 
Molecular genetics. 1p/19q co-deletion was assessed by fluorescence in situ hybridization, 
and MGMT promoter methylation by methylation-specific PCR. IDH1 status was determined 
by immunohistochemistry or gene sequencing. 
Statistics. We used descriptive statistics to characterize the patient population. To test group-
to-group differences the Mann Whitney U test for independent samples was applied. The 
association between baseline imaging parameters and PFS was assessed using the Spearman 
Rank test. The prognostic value of the metabolically active tumor volume on PFS was 
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assessed by receiver-operating-characteristic (ROC) curve analyses.  Patients were divided 
into responders (PFS ≥12, 24, 36, 48, 60 months) and non-responders (PFS <12, 24, 36, 48, 
60 months). Decision cut-off was considered optimal when the product of paired values for 
sensitivity and specificity reached its maximum. Moreover, we determined the area under the 
ROC curve (AUC), its standard error and level of significance as measures of diagnostic 
quality. In addition, we used uni- and multivariate analysis including logistic regression to 
test for associations of histology, PET and MRI response, total dose of TMZ, as well as 
1p/19q co-deletion, IDH1 and MGMT status with PFS. PFS and OS were calculated from the 
start of chemotherapy. Analyses were performed using SigmaStat software (version 3.5; 
Systat Software, Inc.). 
Ethics. Amino acid PET examinations are part of routine clinical investigations in WHO 
grade II glioma patients in Austria, Italy, Switzerland and Germany. All patients gave written 
informed consent before each FET or MET PET investigation. Signed consent is not required 
to perform clinical PET scans in Switzerland. The local ethics committee of Innsbruck 
Medical University approved this retrospective study. In Italy local ethics committee 
approval or patient’s signed consent is not required for retrospective data evaluation. 
 
Results 
Thirty-three patients with WHO grade II astrocytoma (n=6), oligodendroglioma (n=20) or 
oligoastrocytoma (n=7) were enrolled (21 male, 12 female, mean age 37 ± 8 (SD) years, 
range 20 - 53). Prior to chemotherapy 29 patients underwent one, and 4 patients two surgical 
procedures (gross total resection in 6, partial resection in 18, biopsy in 9 patients, Table 1). 
During the whole study no patient received steroids. No patient was treated with either 
previous radiotherapy or PCV (procarbazine-lomustine-vincristine) chemotherapy. 
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Chemotherapy. TMZ chemotherapy started 40 ± 36 months (range 1-126) after the last 
operation because of radiological progression. Chemotherapy was completed as scheduled in 
17 patients, and was interrupted because of patient’s request, toxicity or progression in 1, 7 
and 8 patients, respectively. Hematological adverse effects of CTCAE grades 1, 2 or 3 were 
noted in 5, 3 and 8 patients, respectively. Non-hematological adverse effects consisted of 
nausea in 8 (grades 1-3), fatigue in 6 (grades 2-3), anorexia in 2 (grades 1-2), pruritus in 2 
(grade 2), and local skin infection/zoster in 2 patients (grades 2-3). No secondary neoplasias 
were observed after a median follow up of 74 months. 
Imaging. All patients from Italy were imaged with MET-PET (n=9). Patients from all other 
countries were imaged with FET-PET (n=24). 125 PET and 125 MRI scans each were 
available for evaluation. On MRI 14 patients achieved an objective response (9 minor 
responses, 5 partial responses) (Table 1). Baseline tumor volumes on T2-weighted MRI 
ranged from 4.3 - 450.3 cm3 (75.7  103.9 cm3). Among those 30 patients with baseline 
active tumor defined by PET, volumes ranged from 1.4 - 269.9 cm3 (51.2  51.2 cm3). In line 
with previous work11 we found similar baseline mean tumor uptake ratios for MET (1.43 ± 
0.27) and FET (1.42 ± 0.20). For histological subtypes the following numbers were found: 
T:CBL ratios were 1.43  0.24 in oligodendrogliomas, 1.43  0.27 in oligoastrocytomas, and 
1.28  0.14 in astrocytomas. Peak T:CBL ratios were 2.34  2.29 in oligodendrogliomas, 
2.49  1.99 in oligoastrocytomas, and 1.80  1.58 in astrocytomas. In 3 patients we found no 
active tumor volume at baseline. In these patients the median T:CBL ratio was 1.04  0.02. 
We identified 25 metabolic responders and 5 non-responders. Examples of individual PET 
and MRI responses are presented in Figure 1A. Metabolic responses during chemotherapy 
were best described by an exponential time course, which yielded a reduction of 25% after 
2.3 months (Figure 1B). In contrast, MRI responses on T2-weighted images of the same 
patients were delayed, followed a linear decrease and showed a volume reduction of 25% 
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16.8 months after initiation of chemotherapy (Figure 1C). During chemotherapy the mean 
and peak T:CBL ratios in PET responders were reduced in seven patients by 10-21%. The 
remaining patients showed decreases of less than 7%. This most likely reflects that successful 
chemotherapy reduces the spatial extent of tumor burden, i.e. the active tumor volume, but 
not histology or WHO tumor grade. In contrast to the responses of the active tumor volume 
T:CBL ratios did not follow a linear or an exponential fit (data not shown). 
In PET non-responding patients active tumor volumes increased within six months up to 
354% from baseline. The mean T:CBL ratios increased by 7-11%, and the peak T:CBL ratios 
by 14-36%. All tumors without active volume remained metabolically inactive during 
chemotherapy, and T:CBL ratios remained in a range between 96 and 103% from baseline.  
Molecular genetic data. Information on IDH1 status and LOH1p/19q was available in 26 
patients each, and on MGMT promoter methylation in 24 patients (Table 1). 22 (85%) 
tumors showed IDH1 mutation, 13 (50%) 1p/19q co-deletion, and 20 (83%) MGMT 
promoter methylation. PET responders exhibited IDH1 mutation in 17 (77%) patients, 1p19q 
co-deleted tumors in 11 (85%) patients, and MGMT promoter methylation in 17 (85%) 
patients. 
Seizures. Twenty-two patients presented with seizures before chemotherapy. Tumor size on 
MRI, active PET tumor volume and tumor uptake ratios at baseline were balanced between 
the 2 seizure response groups (Table 2). During chemotherapy antiepileptic drug doses were 
changed to account for low drug serum concentration or for persisting seizures in 5 patients, 
respectively, and were stable in 17 patients. During chemotherapy no patient experienced an 
increase in seizure frequency. Nine patients experienced seizure frequency reductions by 0-
50%, 6 patients by >50%, and 7 patients were seizure-free. Among the 17 patients under 
stable antiepileptic drug doses TMZ reduced the active tumor volumes by 22  27% in group 
I patients, and by 64  28% in group II patients (Figure 2A, p = 0.012, Mann Whitney test). 
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In contrast, neither T:CBL ratio changes nor volume changes on T2-weighted MRI images 
corresponded with seizure frequency reductions (Figure 2B,C). 
Survival. At the time of last follow-up 25 patients were alive, 7 patients were dead, and one 
patient was lost to follow-up. Twenty-six patients progressed at 33  22 months (range, 6 - 
85 months) after the start of chemotherapy, while 7 patients were free from progression at 42 
 22 months (6 - 68). Progression was characterized by neurological deterioration in 23, by 
increase of the T2 lesion in 24, and by appearance of new contrast enhancement in 14 
patients, respectively. Nine patients underwent re-operation for progressive tumor (Table 1). 
Of the progressing patients 7 died 45  19 months (21 - 75) after start of chemotherapy. 
Neither the mean nor the peak T:CBL ratios, nor the magnitude of active tumor volumes 
prior to chemotherapy were predictive for PFS (p = 0.551, p = 0.748 and p = 0.622, 
respectively). In patients with active tumor volume (n = 30) the median PFS was not 
significantly different between metabolic responders (34.3  21.8 months, range 6 - 85) and 
non-responders (27.6  27.2 months, range 6 - 67) (p = 0.605). In contrast, ROC analysis 
yielded a decrease of the active tumor volume of ≥80.5% as an optimal cut-off for the 
prognostication of a PFS of ≥60 months (sensitivity 67%, specificity 90%, accuracy 83%, 
AUC 0.78 ± 0.02; p = 0.018). For the prognostication of a PFS of ≥48 months, a decrease of 
the active tumor volume of ≥64.5% was the optimal threshold (sensitivity 70%, specificity 
58%, accuracy 62%, AUC 0.74 ± 0.11; p = 0.037). The prognostication of a PFS of ≥36 
months (p = 0.154), ≥24 months (p = 0.369), and ≥12 months (p = 0.057), respectively, was 
not significant. 
The PFS in patients without active tumor volume was 29.1  12.4 months (17 - 41). None of 
the following parameters correlated with PFS, either on univariate or multivariate analysis: 
histology (oligodendroglial/oligoastrocytic versus astrocytic tumor, p = 0.988), PET 
(responder versus non-responder, p = 0.734), MRI (objective response (RANO), p = 0.276), 
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total TMZ dose (p = 0.100), IDH1 status (p = 0.088), 1p/19q co-deletion (p = 0.331), MGMT 
promoter methylation status (p = 0.672) (p values shown for univariate analysis). In addition, 
also group-to-group comparisons (imaging responses) did not show differences between 
tumors with or without IDH mutation, between tumors with or without co-deletion 1p19q, or 
between tumors with methylated or unmethylated MGMT promotor (Mann Whitney U test, 
p>0.5 for all comparisons). This may – in part – be explained by the small subgroups 
compared with this test. 
 
Discussion 
In line with previous reports on patients with diffuse cerebral WHO grade II gliomas we have 
observed that chemotherapy responses on MRI occur with variable delay from the initiation 
of treatment.8,9 We noticed a 25% tumor volume reduction on MRI after 16.8 months, 
whereas a 25% reduction of the metabolically active tumor volume on PET was observed as 
early as 2.3 months after initiation of chemotherapy. We excluded patients with enhancing 
tumors on MRI because BBB disruption contributes to non-specific imaging results through 
passive radiotracer influx into the tumor. Thus, we can assume that the amino acid PET 
signal in our patients is specific for active amino acid uptake15,16 which for MET and FET is 
largely mediated by the L-amino acid transport system.17 Accordingly, TMZ chemotherapy 
appears to down-regulate active amino acid transport in WHO grade II gliomas as an early 
response indicator. Altogether, 83% of our patients with active tumor volume were PET 
responders following exposure to TMZ. The long delay between PET and MRI responses 
may reflect that amino acid transporters represent a sensitive nutritional part of tumor cell 
metabolism, whereas signal abnormalities on MRI T2-weighted sequences which may relate 
to tumor cell densities, edema, and alteration of the extracellular matrix respond slowly to 
cytotoxic therapy. 
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Apart from tumor control, TMZ chemotherapy resulted in improved seizure control. At best 
of our knowledge this is the first study showing that seizure control corresponds to the 
magnitude of active tumor volume reductions on amino acid PET. Of note, seizure control 
was neither paralleled by changes in amino acid uptake ratios, nor by decreases of tumor 
volumes as measured by MRI. The latter is in line with recent observations in patients with 
WHO grade II gliomas treated with either radiotherapy18 or TMZ.7 Thus, improved seizure 
control may not rely exclusively on reduced compression of neuronal structures by the tumor 
but also on the reduction of magnitude and spatial extent of local metabolic disequilibrium. 
The mechanisms behind improved seizure control may involve the glutamatergic system. 
Gliomas release glutamate as an excitatory neurotransmitter and activate neuronal glutamate 
receptors.19,20 FET uptake is increased during status epilepticus in the cortex adjacent to 
gliomas and resolves after cessation of epileptic activity.21 Whether transport of both types of 
amino acids, which under physiological conditions use different transport systems, relates to 
each other in gliomas remains to be evaluated. 
The main limitation of our study is its retrospective nature and small sample size. Moreover, 
there was heterogeneity of TMZ regimens and PET and MRI scanners, and molecular data 
were not available for all patients. The variability of TMZ regimens reflects the current lack 
of evidence-based recommendations regarding the optimal regimen and duration of 
chemotherapy.22 However, based on our results, we assume that the time delay between 
amino acid PET and MRI response may be clinically meaningful. Individual PET-guided 
determination of chemotherapy duration in patients showing an early metabolic response and 
response plateau could reduce the risk of toxicity, and lower treatment burden and costs. 
Moreover, one should be cautious to overtreat patients with alkylating chemotherapy which 
can exert a mutagenic effect influencing the risk of malignant transformation.23,24 In 
conclusion, we here characterize the patterns of chemotherapy response on amino acid PET 
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in a cohort of patients with diffuse cerebral WHO grade II gliomas, and report a positive 
correlation between active tumor volume responses, PFS and seizure control. A prospective 
study should validate our findings including MRI, dynamic amino acid PET25 and molecular 
markers to determine whether personalized PET-guided management has impact on survival. 
With regard to the choice of amino acid PET tracer FET seems currently to be most 
promising.26 For the purpose of chemotherapy response assessment FET uptake should be 
quantified as metabolically active volume. This may represent a useful approach to patients 
with WHO grade II gliomas, a rare disease with substantial variation of the clinical course 
and treatment response. 
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Figure Captions 
 
Figure 1. Time course of imaging responses 
A: Examples of individual responses as measured with PET (filled symbols) and MRI (open 
symbols). Square: oligoastrocytoma (#12); triangle: oligodendroglioma (#16); diamond: 
astrocytoma (#6). B, C: Data points represent pooled volume changes measured for the whole 
cohort of metabolic responders during chemotherapy before progression, that is, patients 
were censored at the last PET or MRI prior to progression: black lines correspond to 
exponential fit for PET data (B) (y = 74.61 * exp(-x/158.86) + 24.31) and linear fit for MRI 
data (C) (y = 99.27 – 0.05 * x), respectively. Values on the y-axis represent percent volume 
changes compared to baseline, i.e. before the start of chemotherapy. 
 
Figure 2. Seizure control and imaging responses 
Best imaging responses on active PET volume (A), mean T:CBL uptake ratio (B), MRI T2 
lesion size (C) in patients under stable antiepileptic drug doses (n = 17). Seizure control 
group I = reduction of seizure frequency by 0-50%, seizure control group II = reduction 
>50% or seizure-free patients during chemotherapy. Figure 2A: *p = 0.012 (Mann Whitney 
U test). 
